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mood, positive well-being, self-control, general health, and vital-
ity. Pearson product moment correlation coefﬁcients were calcu-
lated between PGWB scales and A1c (baseline and end of study)
and between changes in PGWB scales and changes in A1c.
RESULTS: At baseline, lower A1c was associated with less
anxiety, less depressed mood, positive well-being, and better
overall psychological general well-being [range: r = -0.20 (posi-
tive well-being) to -0.23 (depressed mood), p < 0.05]. At end of
study, lower A1c was signiﬁcantly associated with overall well-
being and all domains [range: r = -0.19 (general health) to -0.42
(vitality), p < 0.05]. Changes in A1c were associated with
changes in vitality (r = 0.24, n = 111, p < 0.05) but not other
aspects of psychological general well-being. CONCLUSION:
Well-being is associated with patients’ clinical condition at base-
line and end of study as reﬂected in A1c, but, with the exception
of vitality, it is not associated with shorter-term changes in A1c.
Longer term follow-up may be needed to capture the impacts of
drug therapy on symptoms and complications, which are more
directly associated with well-being. Therefore, data collected
regarding patients’ psychological general well-being may serve as
a valuable supplement to clinical endpoints in diabetes drug
therapy evaluations of longer duration than 12 weeks.
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OBJECTIVE: Increase in insulin therapy prescribed to diabetes
patients has led to a demand for simple delivery devices that can
be used for effective, self-injection. Selecting the most appropri-
ate insulin delivery device for a given patient is likely to improve
patient compliance and promote accurate dosing. Perceived
usability and patient preference of the two preﬁlled insulin
analog pen devices (FlexPen and Humalog Pen) were compared.
METHODS: In a randomized, crossover study, 58 subjects (29
male, 29 female, average age 58 ± 16 years) who had not previ-
ously used insulin pen devices were randomized to test either
FlexPen or Humalog Pen for 2 days. The subjects were then
switched to alternate device for 2 days. Device assessments were
carried out at the end of each 2-day test period. Following
instructions, participants made simulated injections into a
sponge on the abdomen to determine the usability of each insulin
device. All subjects were tested for manual function and vision
prior to commencing the study. RESULTS: FlexPen was rated
signiﬁcantly better than Humalog Pen for each of the usability
questions: number legibility (p < 0.001), ease of dose setting 
(p < 0.001), ease of pressing the release button (p < 0.001), sta-
bility during injection (p < 0.001), simplicity (p < 0.001), con-
ﬁrmation of injection (p < 0.001), and appearance (p < 0.01).
No signiﬁcant differences were observed between the two devices
in measures of grip and portability. Overall, 83% subjects pre-
ferred FlexPen; 17% had no preference and no subjects preferred
Humalog Pen. FlexPen was also rated as superior to Humalog
Pen when subgroups of age, manual function and vision were
examined (p < 0.01 for each subgroup comparison of overall
score for each pen). CONCLUSIONS: The perceived usability
advantages of FlexPen were probably due to its scaled analogue
dial (which shows completion of injection) and larger dial
numbers. These results demonstrate that FlexPen achieved
patient preference with a wide range of patients, including those
with impaired vision and manual dexterity.
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OBJECTIVE: Peripheral neuropathy is a frequent complication
of diabetes often resulting in substantial persistent pain. Our goal
was to evaluate the impact of this pain on diabetes patients’ per-
ceived health status. METHODS: Endocrinologists, neurolo-
gists, anesthesiologists, and primary care physicians recruited
patients with a history of painful DPN (N = 255) between April
and October 2003. Patients completed a burden of illness survey
including questions on average and worst pain due to DPN
(modiﬁed Brief Pain Inventory-DPN [m-BPI-DPN] 0–10 scales,
where “0 = no pain” and “10 = pain as bad as you can imagine”),
health status (EuroQoL [EQ-5D]), and global overall health
(0–100 scale, where “0 = worst possible health” and “100 =
perfect health”). RESULTS: Patients were 61 ± 12.8 years old
(51.4% female), had diabetes for 12 ± 10.3 years and painful
DPN for 6.4 ± 6.4 years. Average and worst pain scores were
5.0 ± 2.5 and 5.6 ± 2.8, respectively. The mean EQ-5D Weighted
Health Utility Index score [WHUI] (0–1 scale, 0 = worst health
imaginable, 1 = perfect health) and global health rating were 0.5
± 0.3 and 56.4 ± 23.7, respectively. Patients with “mild” average
pain (ratings of 0 to 3) had signiﬁcantly higher EQ-5D WHUI
(0.65 ± 0.19) and global health ratings (63.8 ± 19.5) compared
to patients with “moderate” (ratings of 4 to 6) 0.52 ± 0.28 and
55.5 ± 21.4, and “severe” (ratings of 7 to 10) average pain 0.21
± 0.33 and 49.3 ± 29.2, respectively; p < 0.05 for most com-
parisons. Increasing levels of worst pain severity from “mild” to
“moderate” to “severe” also resulted in a similar corresponding
decrease in EQ-5D WHUI scores as well as global health ratings,
p < 0.05 for most comparisons. CONCLUSIONS: Pain severity
in diabetic peripheral neuropathy has a signiﬁcant impact on
patients’ perceived health status.
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OBJECTIVE: InDuo is the ﬁrst device to combine an insulin
injector and BG meter. The goal of this study was to assess and
compare patient preference for the integrated system (InDuo®)
versus the standard treatment (syringe vial and separate meter;
SVM). METHODS: In a randomized, multicenter, two-period
crossover study, patients with type 1 diabetes (N = 125, mean
age 42.1 ± 14.3 years, mean A1C 7.9 ± 1.2% and frequency of
screening BG monitoring 3.9/day) were randomized to use of
either InDuo or a separate meter (Ultra One Touch) and syringe
for 6 weeks and then switched to the alternate treatment for 6
additional weeks. Preference and satisfaction questionnaires
were completed at the end of the study. The efﬁcacy, safety and
actual use of InDuo were compared to SVM. RESULTS: Patients
using InDuo reported signiﬁcantly higher overall satisfaction as
